Healthcare M&A is repricing around data, not therapies

PwC's 2026 mid-year review of health industries M&A finds capital shifting decisively toward digital, data and AI-enabled assets, with buyers now building post-deal value through access expansion and data monetisation rather than the traditional cost-synergy playbook.

All insights
Published
7 August 2026
Reading time
1 min
Topics
AI, Consumer Health, Food & Beverage
Written by

Bloom Partners Team

A doctor holding a tablet in conversation with an older patient in a consulting room.

PwC's 2026 mid-year review of health industries M&A finds capital shifting decisively toward digital, data and AI-enabled assets, with buyers now building post-deal value through access expansion and data monetisation rather than the traditional cost-synergy playbook. The uptick in megadeals (above $5 billion) in early 2026 shows strategic buyers chasing assets with proven biology and, increasingly, differentiated data, not just a strong pipeline. Our read: a proprietary data asset is no longer a nice-to-have that sits alongside the therapeutic story, it's becoming the valuation driver itself. Any healthcare business without a clear answer to "what data do we own that a buyer can't replicate" is negotiating from a weaker position than its pipeline alone would suggest. ((PwC))

More insights

Don’t want to miss what comes next?

Bloom Bites brings the thinking behind our work to your inbox, usually before it turns into an article. One mail, no noise, unsubscribe in a click.